Vai al contenuto principale della pagina
Titolo: | AR Signaling in human malignancies : prostate cancer and beyond / / Emmanuel S. Antonarakis, editor |
Pubblicazione: | Basel : , : MDPI AG - Multidisciplinary Digital Publishing Institute, , [2018] |
©2018 | |
Descrizione fisica: | 1 online resource (244 pages) |
Disciplina: | 616.99463 |
Soggetto topico: | Prostate - Cancer |
Prostate - Cancer - Alternative treatment | |
Persona (resp. second.): | AntonarakisEmmanuel S. |
Nota di contenuto: | About the Special Issue Editor v --Preface to "AR Signaling in Human Malignancies: Prostate Cancer and Beyond" -- Emmanuel S. Antonarakis --AR Signaling in Human Malignancies: Prostate Cancer and Beyond -- Michael T. Schweizer and Evan Y. Yu -- AR-Signaling in Human Malignancies: Prostate Cancer and Beyond -- Megan Crumbaker, Leila Khoja and Anthony M. Joshua -- AR Signaling and the PI3K Pathway in Prostate Cancer -- Daisuke Obinata, Kenichi Takayama, Satoru Takahashi and Satoshi Inoue Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential -- Therapeutic Targets for Castration-Resistant Prostate Cancer -- Kurtis Eisermann and Gail Fraizer -- The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer -- Damien A. Leach and Grant Buchanan Stromal Androgen Receptor in Prostate Cancer Development and Progression -- Vito Cucchiara, Joy C. Yang, Vincenzo Mirone, Allen C. Gao, Michael G. Rosenfeld and Christopher P. Evans -- Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy -- Hubert Pakula, Dongxi Xiang and Zhe Li A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland -- Bilal Rahim and Ruth ORegan -- AR Signaling in Breast Cancer -- Ramesh Narayanan and James T. Dalton -- Androgen Receptor: A Complex Therapeutic Target for Breast Cancer -- Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Sayaka Tanaka, Tamami Morisaki, Tsutomu Takashima, Satoru Noda, Naoyoshi Onoda, Masahiko Ohsawa, Kosei Hirakawa and Masaichi Ohira Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer -- Peng Li, Jinbo Chen and Hiroshi Miyamoto -- Androgen Receptor Signaling in Bladder Cancer -- Martin G. Dalin, Philip A. Watson, Alan L. Ho and Luc G. T. Morris -- Androgen Receptor Signaling in Salivary Gland Cancer -- Tatsuo Kanda, Koji Takahashi, Masato Nakamura, Shingo Nakamoto, Shuang Wu, Yuki Haga, Reina Sasaki, Xia Jiang and Osamu Yokosuka -- Androgen Receptor Could Be a Potential Therapeutic Target in Patients with Advanced Hepatocellular Carcinoma. |
Sommario/riassunto: | The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer oncogenesis and disease progression is generally well accepted. What is more poorly understood is the role of AR signaling in other human malignancies. This Special Issue of Cancers initially reviews the role of AR in advanced prostate cancer, and then explores the potential importance of AR signaling in other epithelial malignancies. The first few articles focus on the use of novel AR-targeting therapies in castration-resistant prostate cancer and the mechanisms of resistance to novel antiandrogens, and they also outline the interaction between AR and other cellular pathways, including PI3 kinase signaling, transcriptional regulation, angiogenesis, stromal factors, Wnt signaling, and epigenetic regulation in prostate cancer. The next several articles review the possible role of androgens and AR signaling in breast cancer, bladder cancer, salivary gland cancer, and hepatocellular carcinoma, as well as the potential treatment implications of using antiandrogen therapies in these non-prostatic malignancies. |
Altri titoli varianti: | AR Signaling in Human Malignancies |
Titolo autorizzato: | AR Signaling in human malignancies |
Formato: | Materiale a stampa |
Livello bibliografico | Monografia |
Lingua di pubblicazione: | Inglese |
Record Nr.: | 9910598018003321 |
Lo trovi qui: | Univ. Federico II |
Opac: | Controlla la disponibilità qui |